曲妥珠单抗德鲁司替康治疗脑转移性鳞状肺癌伴免疫相关性垂体炎1例

IF 4.8 2区医学 Q1 PHARMACOLOGY & PHARMACY

Frontiers in Pharmacology Pub Date : 2025-09-11 eCollection Date: 2025-01-01 DOI:10.3389/fphar.2025.1608589

Rui Xu, Jiadi Gan, Jiarui Zhang, Linhui Yang, Yi Liu, Weimin Li, Kaige Wang, Dan Liu

{"title":"曲妥珠单抗德鲁司替康治疗脑转移性鳞状肺癌伴免疫相关性垂体炎1例","authors":"Rui Xu, Jiadi Gan, Jiarui Zhang, Linhui Yang, Yi Liu, Weimin Li, Kaige Wang, Dan Liu","doi":"10.3389/fphar.2025.1608589","DOIUrl":null,"url":null,"abstract":"Immunotherapy is an important part of the first-line treatment for lung squamous cell carcinoma (LUSC) in the current guidelines. However, in case when patients experience immunotherapy-related adverse reactions, immunotherapy may be discontinued. Antibody-drug conjugates (ADCs) may be an alternative treatment if the patient harbors actionable mutations. Herein, we present a case of brain metastatic LUSC harboring HER2 mutation who experienced hypophysitis after immunotherapy. This patient benefited from Trastuzumab Deruxtecan (T-DXd) after discontinuing immunotherapy. Therefore, T-DXd may be an alternative treatment option for LUSC patients with HER2 mutation who are unable to continue immunotherapy.","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1608589"},"PeriodicalIF":4.8000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461255/pdf/","citationCount":"0","resultStr":"{\"title\":\"Trastuzumab Deruxtecan for brain metastatic squamous lung carcinoma with immune-related hypophysitis: a case report.\",\"authors\":\"Rui Xu, Jiadi Gan, Jiarui Zhang, Linhui Yang, Yi Liu, Weimin Li, Kaige Wang, Dan Liu\",\"doi\":\"10.3389/fphar.2025.1608589\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immunotherapy is an important part of the first-line treatment for lung squamous cell carcinoma (LUSC) in the current guidelines. However, in case when patients experience immunotherapy-related adverse reactions, immunotherapy may be discontinued. Antibody-drug conjugates (ADCs) may be an alternative treatment if the patient harbors actionable mutations. Herein, we present a case of brain metastatic LUSC harboring HER2 mutation who experienced hypophysitis after immunotherapy. This patient benefited from Trastuzumab Deruxtecan (T-DXd) after discontinuing immunotherapy. Therefore, T-DXd may be an alternative treatment option for LUSC patients with HER2 mutation who are unable to continue immunotherapy.\",\"PeriodicalId\":12491,\"journal\":{\"name\":\"Frontiers in Pharmacology\",\"volume\":\"16 \",\"pages\":\"1608589\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461255/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fphar.2025.1608589\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2025.1608589","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

免疫治疗是当前指南中肺鳞状细胞癌（LUSC）一线治疗的重要组成部分。然而，如果患者出现免疫治疗相关的不良反应，免疫治疗可能会停止。如果患者携带可操作的突变，抗体-药物偶联物（adc）可能是一种替代治疗方法。在此，我们报告一例脑转移性LUSC携带HER2突变，在免疫治疗后出现垂体炎。该患者在停止免疫治疗后受益于曲妥珠单抗德鲁替康（T-DXd）。因此，T-DXd可能是无法继续免疫治疗的HER2突变LUSC患者的替代治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Trastuzumab Deruxtecan for brain metastatic squamous lung carcinoma with immune-related hypophysitis: a case report.

Immunotherapy is an important part of the first-line treatment for lung squamous cell carcinoma (LUSC) in the current guidelines. However, in case when patients experience immunotherapy-related adverse reactions, immunotherapy may be discontinued. Antibody-drug conjugates (ADCs) may be an alternative treatment if the patient harbors actionable mutations. Herein, we present a case of brain metastatic LUSC harboring HER2 mutation who experienced hypophysitis after immunotherapy. This patient benefited from Trastuzumab Deruxtecan (T-DXd) after discontinuing immunotherapy. Therefore, T-DXd may be an alternative treatment option for LUSC patients with HER2 mutation who are unable to continue immunotherapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.80

自引率

8.90%

发文量

5163

审稿时长

14 weeks

期刊介绍： Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.